Back to Journals » Integrated Blood Pressure Control » Volume 3

Impact of telmisartan in modifying vascular risk

Authors Baguet J, Ormezzano O, Barone-Rochette G

Published 15 June 2010 Volume 2010:3 Pages 81—89

DOI https://doi.org/10.2147/IBPC.S6707

Review by Single-blind

Peer reviewer comments 3


Jean-Philippe Baguet, Olivier Ormezzano, Gilles Barone-Rochette

Clinique de Cardiologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, France

Abstract: Telmisartan, a selective angiotensin II type 1 receptor blocker (ARB), has been investigated in many trials, in particular, in order to assess its antihypertensive effect in various situations and its ability to protect organs susceptible to hypertension. In addition to its antihypertensive properties, it has positive metabolic and vascular effects (partly because of its sustained action). Several large-scale trials have focused on the effect of telmisartan on cardiovascular morbidity and mortality, including comparisons of that with an angiotens-inconverting enzyme inhibitor in subjects at high vascular risk. Telmisartan was used in the largest ARB research programme (the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial [ONTARGET] and Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease [TRANSCEND] trial).

Keywords: angiotensin II receptor blocker cardiovascular risk, hypertension, blood pressure, renin–angiotensin–aldosterone system

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]